



Clinical trial results:

An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine + RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma

Summary

| | |
|--------------------------|-------------------------------|
| EudraCT number | 2009-015504-25 |
| Trial protocol | CZ BE AT DE FR IT GB ES SE NL |
| Global end of trial date | |

Results information

| | |
|--------------------------------|-----------------|
| Result version number | v1 |
| This version publication date | 12 October 2016 |
| First version publication date | 12 October 2016 |

Trial information

Trial identification

| | |
|-----------------------|---------|
| Sponsor protocol code | GO01297 |
|-----------------------|---------|

Additional study identifiers

| | |
|------------------------------------|------------------------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01059630 |
| WHO universal trial number (UTN) | - |
| Other trial identifiers | Genentech Study ID: GAO4753g |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | F. Hoffmann-La Roche AG |
| Sponsor organisation address | Grenzacherstrasse 124, Basel, Switzerland, CH-4070 |
| Public contact | Roche Trial Information Hotline, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com |
| Scientific contact | Roche Trial Information Hotline, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|-------------------|
| Analysis stage | Interim |
| Date of interim/final analysis | 01 September 2014 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 01 September 2014 |
| Global end of trial reached? | No |

Notes:

General information about the trial

Main objective of the trial:

This is a Phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of obinutuzumab (RO5072759, GA101) combined with bendamustine compared with bendamustine alone in participants with rituximab-refractory, Indolent non-Hodgkin lymphoma (iNHL).

Protection of trial subjects:

This study was conducted in accordance with the United States Food and Drug Administration (USFDA) regulations, the International Conference on Harmonisation (ICH) E6 Guideline for Good Clinical Practice, and applicable local, state, and federal laws, as well as other applicable country laws.

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 15 April 2010 |
| Long term follow-up planned | Yes |
| Long term follow-up rationale | Efficacy, Safety |
| Long term follow-up duration | 48 Months |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Austria: 5 |
| Country: Number of subjects enrolled | Belgium: 8 |
| Country: Number of subjects enrolled | Canada: 95 |
| Country: Number of subjects enrolled | Czech Republic: 30 |
| Country: Number of subjects enrolled | France: 78 |
| Country: Number of subjects enrolled | Germany: 4 |
| Country: Number of subjects enrolled | Italy: 16 |
| Country: Number of subjects enrolled | Netherlands: 17 |
| Country: Number of subjects enrolled | Russian Federation: 22 |
| Country: Number of subjects enrolled | Spain: 8 |
| Country: Number of subjects enrolled | Sweden: 13 |
| Country: Number of subjects enrolled | Switzerland: 2 |
| Country: Number of subjects enrolled | United Kingdom: 29 |
| Country: Number of subjects enrolled | United States: 69 |
| Worldwide total number of subjects | 396 |
| EEA total number of subjects | 208 |

Notes:

| Subjects enrolled per age group | |
|---|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 220 |
| From 65 to 84 years | 172 |
| 85 years and over | 4 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 469 participants were screened; out of which 73 participants did not meet the inclusion/exclusion criteria.

Period 1

| | |
|------------------------------|-----------------------------|
| Period 1 title | Induction Period (6 Months) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|--------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Bendamustine Alone |

Arm description:

Participants received Bendamustine 120 milligrams per meter square (mg/m²) Intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.

| | |
|--|----------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Bendamustine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Participants received Bendamustine 120 mg/m² IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.

| | |
|------------------|-----------------------------|
| Arm title | Obinutuzumab + Bendamustine |
|------------------|-----------------------------|

Arm description:

Induction phase: Participants received Bendamustine 90 mg/m² IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6.

Maintenance phase: Participants with complete response (CR), partial response (PR) or stable disease (SD) then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).

| | |
|--|---------------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Obinutuzumab |
| Investigational medicinal product code | |
| Other name | RO5072759, GA101 |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Participants received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6 during induction phase and 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first) during maintenance phase.

| | |
|--|----------------------------------|
| Investigational medicinal product name | Bendamustine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Participants received bendamustine 90 mg/m² IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants.

| Number of subjects in period 1 | Bendamustine Alone | Obinutuzumab + Bendamustine |
|---------------------------------------|--------------------|-----------------------------|
| Started | 202 | 194 |
| Treated | 198 | 194 |
| Completed | 129 | 156 |
| Not completed | 73 | 38 |
| Consent withdrawn by subject | 7 | 2 |
| Physician decision | 2 | 4 |
| Adverse Event | 30 | 15 |
| Death | 2 | 2 |
| Progressive Disease | 14 | 9 |
| Randomized but not Treated | 4 | - |
| Unspecified | 1 | - |
| Induction ongoing | 13 | 6 |

Period 2

| | |
|------------------------------|------------------------------------|
| Period 2 title | Maintenance Period (up to 2 Years) |
| Is this the baseline period? | No |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Arms

| | |
|------------------|-----------------------------|
| Arm title | Obinutuzumab + Bendamustine |
|------------------|-----------------------------|

Arm description:

Induction phase: Participants received Bendamustine 90 mg/m² IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6.

Maintenance phase: Participants with complete response (CR), partial response (PR) or stable disease (SD) then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|----------------------------------|
| Investigational medicinal product name | Bendamustine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Participants received bendamustine 90 mg/m² IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants.

| | |
|--|---------------------------------------|
| Investigational medicinal product name | Obinutuzumab |
| Investigational medicinal product code | |
| Other name | RO5072759, GA101 |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Participants received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6 during induction phase and 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first) during maintenance phase.

| Number of subjects in period 2^[1] | Obinutuzumab + Bendamustine |
|---|------------------------------------|
| Started | 143 |
| Completed | 35 |
| Not completed | 108 |
| Maintenance ongoing | 46 |
| Consent withdrawn by subject | 3 |
| Physician decision | 2 |
| Death | 2 |
| Progressive Disease | 44 |
| Unspecified | 3 |
| Adverse Events | 8 |

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Of all participants who completed induction, 13 participants did not start maintenance.

Baseline characteristics

Reporting groups

| | |
|-----------------------|--------------------|
| Reporting group title | Bendamustine Alone |
|-----------------------|--------------------|

Reporting group description:

Participants received Bendamustine 120 milligrams per meter square (mg/m²) Intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.

| | |
|-----------------------|-----------------------------|
| Reporting group title | Obinutuzumab + Bendamustine |
|-----------------------|-----------------------------|

Reporting group description:

Induction phase: Participants received Bendamustine 90 mg/m² IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6.

Maintenance phase: Participants with complete response (CR), partial response (PR) or stable disease (SD) then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).

| Reporting group values | Bendamustine Alone | Obinutuzumab + Bendamustine | Total |
|---|--------------------|-----------------------------|-------|
| Number of subjects | 202 | 194 | 396 |
| Age categorical Units: Subjects | | | |
| Age continuous Units: years arithmetic mean standard deviation | 61.9 ± 11.4 | 61.9 ± 11.3 | - |
| Gender categorical Units: Subjects | | | |
| Female | 84 | 84 | 168 |
| Male | 118 | 110 | 228 |

End points

End points reporting groups

| | |
|--|-----------------------------|
| Reporting group title | Bendamustine Alone |
| Reporting group description: Participants received Bendamustine 120 milligrams per meter square (mg/m ²) Intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for up to six cycles. | |
| Reporting group title | Obinutuzumab + Bendamustine |
| Reporting group description: Induction phase: Participants received Bendamustine 90 mg/m ² IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with complete response (CR), partial response (PR) or stable disease (SD) then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first). | |
| Reporting group title | Obinutuzumab + Bendamustine |
| Reporting group description: Induction phase: Participants received Bendamustine 90 mg/m ² IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with complete response (CR), partial response (PR) or stable disease (SD) then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first). | |

Primary: Number of Participants With Progressive Disease (PD) as Assessed by Independent Review Committee (IRC) or Death

| | |
|--|--|
| End point title | Number of Participants With Progressive Disease (PD) as Assessed by Independent Review Committee (IRC) or Death ^[1] |
| End point description: PD was assessed by an IRC according to the modified response criteria for indolent Non-Hodgkin's Lymphoma (iNHL) (Modified Cheson et al, 2007). PD was defined as appearance of any new lesion more than 1.5 centimeters (cm) in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50 percent (%) increase from nadir in the sum of product diameter (SPD) of any previously involved nodes, or in a single involved node, or the size of other lesions (example: splenic or hepatic nodules). To be considered PD, a lymph node with a diameter of the short axis of less than (<) 1.0 cm must increase by greater than or equal to (≥) 50% and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node greater than (>) 1 cm in its short axis. Intent to treat (ITT) population included all participants who were randomized in the study. | |
| End point type | Primary |
| End point timeframe: Baseline until PD or death, whichever occurred first (assessed at baseline, 14 days prior to Cycle [Cy] 4 Day 1 [1 Cy=28days], 28–42 days after Cy 6 Day 1, then every 3 months up to 2 years and every 6 months for next 2 years [up to 4.5 years overall]) | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned for this endpoint.

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|-----------------------------|--------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 202 | 194 | | |
| Units: participants | | | | |
| number (not applicable) | 104 | 71 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Progression-Free Survival (PFS) as Assessed by IRC

| | |
|-----------------|--|
| End point title | Progression-Free Survival (PFS) as Assessed by IRC |
|-----------------|--|

End point description:

PFS: time from randomization to first occurrence of PD or death as assessed by IRC according to modified response criteria for iNHL (modified Cheson et al, 2007). PD: appearance of any new lesion more than 1.5 cm in any axis during or at end of therapy, even if other lesions decrease in size; at least 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions (e.g., splenic or hepatic nodules). To be PD, lymph node with diameter of short axis of <1.0 cm must increase by $\geq 50\%$ and to size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in long axis; at least 50% increase in longest diameter of any single previously identified node >1 cm in its short axis. PFS was estimated using Kaplan-Meier method and 95% confidence interval (CI) for median was computed using method of Brookmeyer and Crowley. ITT population. The number 99999 signified data could not be estimated due to higher (>50%) number of censored participants.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline until PD or death, whichever occurred first (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28–42 days after Cy 6 Day 1, then every 3 months up to 2 years and every 6 months for next 2 years [up to 4.5 years overall])

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|----------------------------------|---------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 202 | 194 | | |
| Units: months | | | | |
| median (confidence interval 95%) | 14.9 (12.8 to 16.6) | 99999 (22.5 to 99999) | | |

Statistical analyses

| | |
|----------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 1 |
|----------------------------|------------------------|

Statistical analysis description:

Randomization was stratified for iNHL subtype (follicular versus other), refractory type (rituximab monotherapy versus rituximab + chemotherapy), number of prior therapies (less than or equal to 2 versus greater than 2) and geographic region.

| | |
|-------------------|--|
| Comparison groups | Bendamustine Alone v Obinutuzumab + Bendamustine |
|-------------------|--|

| | |
|---|-------------------|
| Number of subjects included in analysis | 396 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.0001 |
| Method | Logrank |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.55 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.4 |
| upper limit | 0.74 |

Secondary: Number of Participants With PD or Death as Assessed by Investigator

| | |
|-----------------|---|
| End point title | Number of Participants With PD or Death as Assessed by Investigator |
|-----------------|---|

End point description:

PD was assessed by an investigator according to the modified response criteria for iNHL (modified Cheson et al, 2007). PD was defined as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules). To be considered PD, a lymph node with a diameter of the short axis of <1.0 cm must increase by $\geq 50\%$ and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least a 50% increase in the longest diameter of any single previously identified node >1 cm in its short axis. ITT population.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline until PD or death, whichever occurred first (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28–42 days after Cy 6 Day 1, then every 3 months up to 2 years and every 6 months for next 2 years [up to 4.5 years overall])

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|-----------------------------|--------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 202 | 194 | | |
| Units: participants | | | | |
| number (not applicable) | 115 | 77 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: PFS as Assessed by Investigator

| | |
|-----------------|---------------------------------|
| End point title | PFS as Assessed by Investigator |
|-----------------|---------------------------------|

End point description:

PFS: time from randomization to first occurrence of PD as assessed by investigator according to

modified response criteria for iNHL (Modified Cheson et al, 2007), or death from any cause on study. PD: appearance of any new lesion more than 1.5 cm in any axis during/at end of therapy, even if other lesions decreases in size; at least 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions. To be considered PD, lymph node with diameter of the short axis of <1.0 cm must increase by $\geq 50\%$ and to a size of 1.5 multiplied by 1.5 cm or more than 1.5 cm in the long axis; at least 50% increase in the longest diameter of any single previously identified node >1 cm in its short axis. PFS was estimated using Kaplan-Meier method and 95% CI for median was computed using method of Brookmeyer and Crowley. ITT population. The number 99999 signified data could not be estimated due to higher (>50%) number of censored participants.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline until PD or death, whichever occurred first (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28–42 days after Cy 6 Day 1, then every 3 months up to 2 years and every 6 months for next 2 years [up to 4.5 years overall])

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|----------------------------------|--------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 202 | 194 | | |
| Units: Months | | | | |
| median (confidence interval 95%) | 14 (11.7 to 16) | 29.2 (20.2 to 99999) | | |

Statistical analyses

| | |
|----------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 1 |
|----------------------------|------------------------|

Statistical analysis description:

Randomization was stratified for iNHL subtype (follicular versus other), refractory type (rituximab monotherapy versus rituximab + chemotherapy), number of prior therapies (less than or equal to 2 versus greater than 2) and geographic region.

| | |
|---|--|
| Comparison groups | Bendamustine Alone v Obinutuzumab + Bendamustine |
| Number of subjects included in analysis | 396 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | < 0.0001 |
| Method | Logrank |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.52 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.39 |
| upper limit | 0.7 |

Secondary: Percentage of Participants With Objective Response as Assessed by IRC and Investigator

| | |
|-----------------|--|
| End point title | Percentage of Participants With Objective Response as Assessed by IRC and Investigator |
|-----------------|--|

End point description:

Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. ITT population. Here, number of participants analyzed signified those participants who had at least one post-baseline assessment.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline until PD or death, whichever occurred first (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28–42 days after Cy 6 Day 1, then every 3 months up to 12 months overall)

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|-----------------------------------|-----------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 197 | 192 | | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| IRC Assessment | 76.6 (70.11 to 82.37) | 78.6 (72.17 to 84.22) | | |
| Investigator Assessment | 82.2 (76.17 to 87.3) | 82.8 (76.72 to 87.86) | | |

Statistical analyses

| Statistical analysis title | Statistical Analysis 1 |
|----------------------------|------------------------|
|----------------------------|------------------------|

Statistical analysis description:

Statistical Analysis 1 for Percentage of Participants With Objective Response as Assessed by IRC.

| | |
|---|--|
| Comparison groups | Bendamustine Alone v Obinutuzumab + Bendamustine |
| Number of subjects included in analysis | 389 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.743 |
| Method | Cochran-Mantel-Haenszel |
| Parameter estimate | Difference in response rate |
| Point estimate | 2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -6.56 |
| upper limit | 10.55 |

| Statistical analysis title | Statistical Analysis 2 |
|----------------------------|------------------------|
|----------------------------|------------------------|

Statistical analysis description:

Statistical Analysis 2 for Percentage of Participants With Objective Response as Assessed by Investigator.

| | |
|---|--|
| Comparison groups | Bendamustine Alone v Obinutuzumab + Bendamustine |
| Number of subjects included in analysis | 389 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.8946 |
| Method | Cochran-Mantel-Haenszel |
| Parameter estimate | Difference in response rate |
| Point estimate | 0.58 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -7.25 |
| upper limit | 8.41 |

Secondary: Percentage of Participants With Best Overall Response (BOR) as Assessed by IRC and Investigator

| | |
|-----------------|---|
| End point title | Percentage of Participants With Best Overall Response (BOR) as Assessed by IRC and Investigator |
|-----------------|---|

End point description:

BOR: best response for a participant, observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by baseline scan and no new sites; no increase in size of the other nodes, liver, or spleen; SD: Failing to attain the criteria needed for a CR or PR, but not fulfilling those for PD, PD: appearance of any new lesion more than 1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions. ITT population. Here, number of participants analyzed signified those participants who had at least one post-baseline assessment.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline until PD or death, whichever occurred first (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28–42 days after Cy 6 Day 1, then every 3 months up to 12 months overall)

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|-----------------------------------|-----------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 197 | 192 | | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| IRC Assessment: CR | 17.3 (12.26 to 23.27) | 16.7 (11.69 to 22.71) | | |
| IRC Assessment: PR | 59.4 (52.18 to 66.31) | 62 (54.71 to 68.87) | | |
| IRC Assessment: SD | 11.7 (7.55 to 17) | 10.9 (6.9 to 16.23) | | |
| IRC Assessment: PD | 4.1 (1.77 to 7.84) | 4.7 (2.17 to 8.71) | | |

| | | | | |
|---|-----------------------|-----------------------|--|--|
| IRC Assessment: Unable to evaluate | 0.5 (0.01 to 2.8) | 1 (0.13 to 3.71) | | |
| IRC Assessment: Missing | 7.1 (3.94 to 11.64) | 4.7 (2.17 to 8.71) | | |
| Investigator Assessment: CR | 21.3 (15.82 to 27.71) | 22.4 (16.71 to 28.96) | | |
| Investigator Assessment: PR | 60.9 (53.72 to 67.77) | 60.4 (53.12 to 67.38) | | |
| Investigator Assessment: SD | 6.6 (3.56 to 11.02) | 6.8 (3.65 to 11.3) | | |
| Investigator Assessment: PD | 3.6 (1.44 to 7.18) | 5.7 (2.89 to 10.02) | | |
| Investigator Assessment: Unable to evaluate | 1.5 (0.32 to 4.39) | 0.5 (0.01 to 2.87) | | |
| Investigator Assessment: Missing | 6.1 (3.19 to 10.4) | 4.2 (1.82 to 8.04) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Objective Response at the End of Induction Treatment as Assessed by IRC and Investigator

| | |
|-----------------|--|
| End point title | Percentage of Participants With Objective Response at the End of Induction Treatment as Assessed by IRC and Investigator |
|-----------------|--|

End point description:

Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. ITT population. Here, number of participants analyzed signified those participants who had reached the end of induction treatment response assessment.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline until end of induction treatment (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28–42 days after Cy 6 Day 1)

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|-----------------------------------|-----------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 189 | 188 | | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| IRC Assessment | 63 (55.65 to 69.86) | 69.1 (62.02 to 75.67) | | |
| Investigator Assessment | 67.7 (60.56 to 74.33) | 76.6 (69.88 to 82.45) | | |

Statistical analyses

| | |
|--|--|
| Statistical analysis title | Statistical Analysis 1 |
| Statistical analysis description: Statistical Analysis 1 for Percentage of Participants With Objective Response at the End of Induction Treatment as Assessed by IRC. | |
| Comparison groups | Bendamustine Alone v Obinutuzumab + Bendamustine |
| Number of subjects included in analysis | 377 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.3062 |
| Method | Cochran-Mantel-Haenszel |
| Parameter estimate | Difference in response rate |
| Point estimate | 6.19 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.64 |
| upper limit | 16.02 |

| | |
|---|--|
| Statistical analysis title | Statistical Analysis 2 |
| Statistical analysis description: Statistical Analysis 2 for Percentage of Participants With Objective Response at the End of Induction Treatment as Assessed by Investigator. | |
| Comparison groups | Bendamustine Alone v Obinutuzumab + Bendamustine |
| Number of subjects included in analysis | 377 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.0506 |
| Method | Cochran-Mantel-Haenszel |
| Parameter estimate | Difference in response rate |
| Point estimate | 8.87 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.42 |
| upper limit | 18.16 |

Secondary: Percentage of Participants With BOR at the End of Induction Treatment as Assessed by IRC and Investigator

| | |
|-----------------|---|
| End point title | Percentage of Participants With BOR at the End of Induction |
|-----------------|---|

End point description:

BOR: best response for a participant, observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by baseline scan and no new sites; no increase in size of the other nodes, liver, or spleen; SD: Failing to attain the criteria needed for a CR or PR, but not fulfilling those for PD, PD: appearance of any new lesion more than 1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions. ITT population. Here, number of participants analyzed signified those participants who had reached the end of induction treatment response assessment.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline until end of induction treatment (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28–42 days after Cy 6 Day 1)

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|---|-----------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 189 | 188 | | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| IRC Assessment: CR | 12.2 (7.87 to 17.7) | 11.2 (7.05 to 16.57) | | |
| IRC Assessment: PR | 50.8 (43.44 to 58.12) | 58 (50.58 to 65.12) | | |
| IRC Assessment: SD | 9.5 (5.74 to 14.63) | 10.1 (6.2 to 15.33) | | |
| IRC Assessment: PD | 9 (5.33 to 14.01) | 9 (5.36 to 14.08) | | |
| IRC Assessment: Unable to Evaluate | 2.6 (0.86 to 6.07) | 2.1 (0.58 to 5.36) | | |
| IRC Assessment: Missing | 15.9 (10.97 to 21.88) | 9.6 (5.77 to 14.71) | | |
| Investigator Assessment: CR | 15.9 (10.97 to 21.88) | 16.5 (11.49 to 22.58) | | |
| Investigator Assessment: PR | 51.9 (44.48 to 59.16) | 60.1 (52.73 to 67.16) | | |
| Investigator Assessment: SD | 3.2 (1.17 to 6.78) | 4.3 (1.85 to 8.21) | | |
| Investigator Assessment: PD | 11.1 (7.01 to 16.48) | 9 (5.36 to 14.08) | | |
| Investigator Assessment: Unable to Evaluate | 3.2 (1.17 to 6.78) | 0.5 (0.01 to 2.93) | | |
| Investigator Assessment: Missing | 14.8 (10.08 to 20.69) | 9.6 (5.77 to 14.71) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DoR) as Assessed by IRC

| | |
|---|---|
| End point title | Duration of Response (DoR) as Assessed by IRC |
| End point description: | |
| DoR: time from first objective response of CR/PR to first occurrence of PD/relapse/death from any cause. CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy; liver, spleen returned to normal size (if enlarged at baseline); if bone marrow was involved by lymphoma prior to treatment, infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to baseline scan and no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic, hepatic nodules; involvement of other organs is usually assessable; no presence of measurable disease. PD: appearance of any new lesion >1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions. DoR was estimated using Kaplan-Meier method. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline until PD or death, whichever occurred first (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28–42 days after Cy 6 Day 1, then every 3 months up to 2 years and every 6 months for next 2 years [up to 4.5 years overall]) | |

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|----------------------------------|--------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 154 | 154 | | |
| Units: months | | | | |
| median (confidence interval 95%) | 13.2 (11 to 14.1) | 99999 (25.4 to 99999) | | |

Statistical analyses

| | |
|--|--|
| Statistical analysis title | Statistical Analysis 1 |
| Statistical analysis description: | |
| Randomization was stratified for iNHL subtype (follicular versus other), refractory type (rituximab monotherapy versus rituximab + chemotherapy), number of prior therapies (less than or equal to 2 versus greater than 2) and geographic region. | |
| Comparison groups | Bendamustine Alone v Obinutuzumab + Bendamustine |
| Number of subjects included in analysis | 308 |
| Analysis specification | Pre-specified |
| Analysis type | |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.42 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.29 |
| upper limit | 0.61 |

Secondary: Disease-Free Survival (DFS) in Participants With CR as Assessed by IRC

| | |
|-----------------|--|
| End point title | Disease-Free Survival (DFS) in Participants With CR as Assessed by IRC |
|-----------------|--|

End point description:

DFS: time from first occurrence of documented CR until progression on basis of IRC assessments (as per modified response criteria for iNHL [Modified Cheson et al, 2007]) or death from any cause on study.
 CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms, liver and spleen returned to normal size if enlarged at baseline, If bone marrow was involved by lymphoma prior to treatment, infiltrate must have cleared on repeat bone marrow biopsy. PD: appearance of any new lesion >1.5 cm in any axis during/at end of therapy, even if other lesions decreases in size; at least 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions. DFS was estimated using Kaplan-Meier method. ITT population. Number of participants analyzed signified participants who had an objective response of CR. Number 99999 signified data could not be estimated due to higher (>50%) number of censored participants.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline until PD or death, whichever occurred first (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28–42 days after Cy 6 Day 1, then every 3 months up to 2 years and every 6 months for next 2 years [up to 4.5 years overall])

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|----------------------------------|---------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 35 | 42 | | |
| Units: months | | | | |
| median (confidence interval 95%) | 13.2 (8.2 to 99999) | 99999 (99999 to 99999) | | |

Statistical analyses

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 1 |
|-----------------------------------|------------------------|

Statistical analysis description:

Randomization was stratified for iNHL subtype (follicular versus other), refractory type (rituximab monotherapy versus rituximab + chemotherapy), number of prior therapies (less than or equal to 2 versus greater than 2) and geographic region.

| | |
|---|--|
| Comparison groups | Bendamustine Alone v Obinutuzumab + Bendamustine |
| Number of subjects included in analysis | 77 |
| Analysis specification | Pre-specified |
| Analysis type | |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.09 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.02 |
| upper limit | 0.4 |

Secondary: Event-free Survival (EFS) as Assessed by IRC

| | |
|-----------------|--|
| End point title | Event-free Survival (EFS) as Assessed by IRC |
|-----------------|--|

End point description:

EFS was defined as the time between the date of randomization and the date of PD/relapse based on IRC assessments (as per modified response criteria for iNHL [Modified Cheson et al, 2007]), death from any cause on study, or start of a new anti-lymphoma therapy. PD: appearance of any new lesion >1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in a single involved node, or size of other lesions. EFS was estimated using Kaplan-Meier method. ITT population. The number 99999 signified data could not be estimated due to higher (>50%) number of censored participants.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline until PD or death, whichever occurred first (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28–42 days after Cy 6 Day 1, then every 3 months up to 2 years and every 6 months for next 2 years [up to 4.5 years overall])

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|----------------------------------|---------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 202 | 194 | | |
| Units: months | | | | |
| median (confidence interval 95%) | 13.7 (11.4 to 16.2) | 26.8 (14.1 to 99999) | | |

Statistical analyses

| | |
|----------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 1 |
|----------------------------|------------------------|

Statistical analysis description:

Randomization was stratified for iNHL subtype (follicular versus other), refractory type (rituximab monotherapy versus rituximab + chemotherapy), number of prior therapies (less than or equal to 2 versus greater than 2) and geographic region.

| | |
|---|--|
| Comparison groups | Bendamustine Alone v Obinutuzumab + Bendamustine |
| Number of subjects included in analysis | 396 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.0001 |
| Method | Logrank |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.57 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.43 |
| upper limit | 0.76 |

Secondary: Percentage of Participants Who Died

| | |
|-----------------|-------------------------------------|
| End point title | Percentage of Participants Who Died |
|-----------------|-------------------------------------|

End point description:

ITT population.

| | |
|--|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline until death (up to 4.5 years overall) | |

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|-----------------------------------|--------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 202 | 194 | | |
| Units: percentage of participants | | | | |
| number (not applicable) | 20.3 | 17.5 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (OS)

| | |
|---|-----------------------|
| End point title | Overall Survival (OS) |
| End point description: | |
| OS was defined as the time between the date of randomization and the date of death from any cause. OS was estimated using Kaplan-Meier method and 95% CI for median was computed using the method of Brookmeyer and Crowley. ITT population. The number 99999 signified data could not be estimated due to higher (>50%) number of censored participants. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline until death (up to 4.5 years overall) | |

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|----------------------------------|-----------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 202 | 194 | | |
| Units: months | | | | |
| median (confidence interval 95%) | 99999 (39.8 to 99999) | 99999 (99999 to 99999) | | |

Statistical analyses

| | |
|--|------------------------|
| Statistical analysis title | Statistical Analysis 1 |
| Statistical analysis description: | |
| Randomization was stratified for iNHL subtype (follicular versus other), refractory type (rituximab monotherapy versus rituximab + chemotherapy), number of prior therapies (less than or equal to 2 versus greater than 2) and geographic region. | |

| | |
|---|--|
| Comparison groups | Bendamustine Alone v Obinutuzumab + Bendamustine |
| Number of subjects included in analysis | 396 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.4017 |
| Method | Logrank |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.82 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.52 |
| upper limit | 1.3 |

Secondary: Change From Baseline (CFB) in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)-Physical Well Being Sub-scale Score

| | |
|-----------------|---|
| End point title | Change From Baseline (CFB) in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)-Physical Well Being Sub-scale Score |
|-----------------|---|

End point description:

FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0 (Not at all) to 4 (Very much). Total score range: 0-168. Physical well-being sub-scale includes 7 items measured on 0-4 point scale; total score ranges from 0-28. Higher scores indicates better participant-reported outcome (PRO)/quality of life (QoL). In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction); extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up). ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome and "n" signified those participants who were evaluable for a specified time point. The number 99999 signified data not available either because no participant or only one participant was evaluable.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Day 1 of Cycles 1, 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6 and 18

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|--|--------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 181 | 177 | | |
| Units: units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=181, 177) | 22.63 (± 5.16) | 22.72 (± 4.65) | | |
| CFB at Cycle 1 Day 1 (n=0, 0) | 99999 (± 99999) | 99999 (± 99999) | | |
| CFB at Cycle 3 Day 1 (n=146, 147) | -1.78 (± 5.47) | -0.77 (± 4.13) | | |
| CFB at Cycle 4 Day 1 (n=5, 2) | -6.8 (± 4.21) | -3 (± 2.83) | | |
| CFB at Cycle 5 Day 1 (n=130, 137) | -1.99 (± 5.07) | -0.77 (± 4.22) | | |
| CFB at End of Induction Treatment (n=132, 135) | -0.96 (± 5.23) | -0.63 (± 4.71) | | |

| | | | | |
|---|----------------|----------------|--|--|
| CFB at Follow-up Month 2 (n=91, 119) | 0.42 (± 5.21) | 0.57 (± 4.46) | | |
| CFB at Follow-up Month 4 (n= 80, 108) | 0.36 (± 4.44) | 0.84 (± 4.32) | | |
| CFB at Follow-up Month 6 (n= 67, 94) | 0.31 (± 3.74) | 0.77 (± 3.62) | | |
| CFB at Follow-up Month 8 (n= 62, 86) | -0.12 (± 3.42) | 0.78 (± 3.82) | | |
| CFB at Follow-up Month 10 (n= 47, 71) | -0.28 (± 4.42) | 0.47 (± 4.01) | | |
| CFB at Follow-up Month 12 (n= 38, 70) | 0.5 (± 4.26) | 0.66 (± 4.6) | | |
| CFB at Follow-up Month 14 (n= 32, 62) | 0.14 (± 4.24) | 0.5 (± 4) | | |
| CFB at Follow-up Month 16 (n= 26, 59) | -0.47 (± 3.36) | 0.86 (± 3.62) | | |
| CFB at Follow-up Month 18 (n= 23, 50) | -0.22 (± 4.03) | 0.6 (± 4.27) | | |
| CFB at Follow-up Month 20 (n= 22, 41) | -0.31 (± 3.96) | 0.35 (± 4.23) | | |
| CFB at Follow-up Month 22 (n=16, 38) | -0.73 (± 4.06) | -0.15 (± 5.32) | | |
| CFB at Follow-up Month 24 (n=15, 33) | -1.23 (± 3.81) | 0.35 (± 5.42) | | |
| CFB at Final Follow-up (n=59, 58) | -0.09 (± 4.15) | 0.12 (± 5.17) | | |
| CFB at Extension Follow-up Month 6 (n= 7, 18) | 0.31 (± 2.6) | 1.09 (± 5.33) | | |
| CFB at Extension Follow-up Month 18 (n= 1, 1) | 1 (± 99999) | 7 (± 99999) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: CFB in FACT-Lym-Social/Family Well-being Sub-scale Score

| | |
|-----------------|--|
| End point title | CFB in FACT-Lym-Social/Family Well-being Sub-scale Score |
|-----------------|--|

End point description:

FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0 (Not at all) to 4 (Very much). Total score range: 0-168. Social/family well-being sub-scale includes 7 items measured on 0-4 point scale; total score ranges from 0-28. Higher scores indicates better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction); extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up). ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome and "n" signified those participants who were evaluable for a specified time point. The number 99999 signified data not available either because no participant or only one participant was evaluable.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Day 1 of Cycles 1, 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6 and 18

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|--------------------------------------|--------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 180 | 181 | | |
| Units: units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=180, 181) | 22.14 (± 5.58) | 22.17 (± 5.48) | | |
| CFB at Cycle 1 Day 1 (n=0, 0) | 99999 (± 99999) | 99999 (± 99999) | | |

| | | | | |
|--|----------------|----------------|--|--|
| CFB at Cycle 3 Day 1 (n=145, 151) | -0.35 (± 3.39) | -0.1 (± 3.94) | | |
| CFB at Cycle 4 Day 1 (n=5, 3) | -1 (± 3.67) | 3.11 (± 2.83) | | |
| CFB at Cycle 5 Day 1 (n=129, 141) | -0.82 (± 3.45) | -0.39 (± 4.4) | | |
| CFB at End of Induction Treatment (n=131, 138) | -1.06 (± 4.69) | -0.91 (± 3.62) | | |
| CFB at Follow-up Month 2 (n=90, 123) | -0.48 (± 3.89) | -0.59 (± 5.54) | | |
| CFB at Follow-up Month 4 (n=80, 111) | 0.09 (± 3.76) | -0.26 (± 5.2) | | |
| CFB at Follow-up Month 6 (n=67, 95) | -0.14 (± 2.84) | -0.07 (± 4.81) | | |
| CFB at Follow-up Month 8 (n=62, 88) | -0.48 (± 3.48) | -0.47 (± 5.19) | | |
| CFB at Follow-up Month 10 (n=47, 73) | 0.05 (± 3.45) | 0.16 (± 5.38) | | |
| CFB at Follow-up Month 12 (n=38, 72) | 0.13 (± 2.31) | -0.14 (± 5.53) | | |
| CFB at Follow-up Month 14 (n=32, 64) | 0.82 (± 3.32) | -0.17 (± 3.86) | | |
| CFB at Follow-up Month 16 (n=26, 61) | 0.41 (± 3.68) | 0.4 (± 5.63) | | |
| CFB at Follow-up Month 18 (n=23, 51) | 0.3 (± 3.89) | 0.49 (± 6.02) | | |
| CFB at Follow-up Month 20 (n=22, 43) | -0.82 (± 4.61) | 0.82 (± 6.14) | | |
| CFB at Follow-up Month 22 (n=16, 40) | -0.97 (± 5.47) | -0.39 (± 5.41) | | |
| CFB at Follow-up Month 24 (n=15, 34) | -0.97 (± 2.56) | 0.23 (± 4.32) | | |
| CFB at Final Follow-up (n=59, 59) | -0.47 (± 3.34) | -0.3 (± 5.36) | | |
| CFB at Extension Follow-up Month 6 (n=7, 18) | -0.64 (± 2.68) | 0.62 (± 4.01) | | |
| CFB at Extension Follow-up Month 18 (n=1, 1) | -1 (± 99999) | 10 (± 99999) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: CFB in FACT-Lym-Emotional Well Being Sub-scale Score

| | |
|-----------------|--|
| End point title | CFB in FACT-Lym-Emotional Well Being Sub-scale Score |
|-----------------|--|

End point description:

FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0 (Not at all) to 4 (Very much). Total score range: 0-168. Emotional well-being sub-scale includes 6 items measured on 0-4 point scale; total score ranges from 0-24. Higher scores indicates better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction); extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up). ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome and "n" signified those participants who were evaluable for a specified time point. The number 99999 signified data not available either because no participant or only one participant was evaluable.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Day 1 of Cycles 1, 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6 and 18

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|--|--------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 183 | 184 | | |
| Units: units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=183, 184) | 17.43 (± 4.44) | 17.73 (± 4.33) | | |
| CFB at Cycle 1 Day 1 (n=0, 0) | 99999 (± 99999) | 99999 (± 99999) | | |
| CFB at Cycle 3 Day 1 (n=147, 156) | 0.54 (± 3.07) | 0.75 (± 3.14) | | |
| CFB at Cycle 4 Day 1 (n=5, 3) | -0.6 (± 3.85) | 3.4 (± 4.42) | | |
| CFB at Cycle 5 Day 1 (n=131, 144) | 0.32 (± 3.11) | 0.5 (± 3.59) | | |
| CFB at End of Induction Treatment (n=133, 138) | 0.53 (± 3.59) | 0.48 (± 3.97) | | |
| CFB at Follow-up Month 2 (n=90, 124) | 0.74 (± 4.03) | 0.58 (± 3.67) | | |
| CFB at Follow-up Month 4 (n=81, 110) | 1.37 (± 3.5) | 0.88 (± 3.41) | | |
| CFB at Follow-up Month 6 (n=68, 97) | 0.94 (± 3.42) | 0.97 (± 3.29) | | |
| CFB at Follow-up Month 8 (n=62, 89) | 0.29 (± 3.55) | 0.76 (± 3.23) | | |
| CFB at Follow-up Month 10 (n=46, 73) | 0.72 (± 3.59) | 1.17 (± 2.95) | | |
| CFB at Follow-up Month 12 (n=38, 72) | -0.08 (± 3.98) | 0.84 (± 3.01) | | |
| CFB at Follow-up Month 14 (n=32, 64) | 0.43 (± 3.48) | 0.93 (± 3.58) | | |
| CFB at Follow-up Month 16 (n=26, 62) | 0.08 (± 3.77) | 0.95 (± 3.49) | | |
| CFB at Follow-up Month 18 (n=22, 52) | 0.41 (± 3.1) | 0.92 (± 3.01) | | |
| CFB at Follow-up Month 20 (n=22, 44) | -0.14 (± 2.82) | 0.84 (± 4.45) | | |
| CFB at Follow-up Month 22 (n=16, 40) | -0.38 (± 2.7) | 0.88 (± 3.84) | | |
| CFB at Follow-up Month 24 (n=15, 35) | -0.2 (± 3.19) | 0.95 (± 3.76) | | |
| CFB at Final Follow-up (n=58, 61) | 0.03 (± 3.85) | 0.1 (± 4.9) | | |
| CFB at Extension Follow-up Month 6 (n=7, 18) | -0.43 (± 5.09) | 1.21 (± 4.68) | | |
| CFB at Extension Follow-up Month 18 (n=1, 1) | 1 (± 99999) | 8 (± 99999) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: CFB in FACT-Lym-Functional Well Being Sub-scale Score

| | |
|-----------------|---|
| End point title | CFB in FACT-Lym-Functional Well Being Sub-scale Score |
|-----------------|---|

End point description:

FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0 (Not at all) to 4 (Very much). Total score range: 0-168. Functional well-being sub-scale includes 7 items measured on 0-4 point scale; total score ranges from 0-28. Higher scores indicates better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction); extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up). ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome and "n" signified those participants who were evaluable for a specified time point. The number 99999 signified data not available either because no participant or only one participant was evaluable.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Day 1 of Cycles 1, 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|--|----------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 183 | 186 | | |
| Units: units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=183, 186) | 18 (\pm 6.18) | 17.84 (\pm 6.07) | | |
| CFB at Cycle 1 Day 1 (n=0, 0) | 99999 (\pm 99999) | 99999 (\pm 99999) | | |
| CFB at Cycle 3 Day 1 (n=147, 158) | -0.64 (\pm 4.7) | 0.39 (\pm 4.74) | | |
| CFB at Cycle 4 Day 1 (n=5, 3) | -0.8 (\pm 2.28) | 1.78 (\pm 4.91) | | |
| CFB at Cycle 5 Day 1 (n=131, 146) | -0.88 (\pm 5.04) | 0.67 (\pm 5.48) | | |
| CFB at End of Induction Treatment (n=133, 140) | -0.58 (\pm 5.68) | 0 (\pm 5.35) | | |
| CFB at Follow-up Month 2 (n=90, 125) | 0.32 (\pm 5.54) | 0.74 (\pm 5.48) | | |
| CFB at Follow-up Month 4 (n=81, 112) | 0.36 (\pm 5.14) | 1.3 (\pm 5.77) | | |
| CFB at Follow-up Month 6 (n=67, 97) | 0.81 (\pm 4.65) | 1.58 (\pm 5.05) | | |
| CFB at Follow-up Month 8 (n=62, 89) | -0.21 (\pm 4.38) | 1.03 (\pm 5.75) | | |
| CFB at Follow-up Month 10 (n=47, 74) | 1 (\pm 4.42) | 1.23 (\pm 5.93) | | |
| CFB at Follow-up Month 12 (n=38, 73) | 1.11 (\pm 4.82) | 1.96 (\pm 6.63) | | |
| CFB at Follow-up Month 14 (n=32, 64) | 1.47 (\pm 4.53) | 1.39 (\pm 5.12) | | |
| CFB at Follow-up Month 16 (n=26, 62) | 0.89 (\pm 4.17) | 2.14 (\pm 6.14) | | |
| CFB at Follow-up Month 18 (n=22, 52) | 0.1 (\pm 4.98) | 1.87 (\pm 6.77) | | |
| CFB at Follow-up Month 20 (n=22, 44) | -0.81 (\pm 4.55) | 1.52 (\pm 7.31) | | |
| CFB at Follow-up Month 22 (n=16, 41) | -1.74 (\pm 4.9) | 0.71 (\pm 6.06) | | |
| CFB at Follow-up Month 24 (n=15, 35) | -1.86 (\pm 4.46) | 1.5 (\pm 6.84) | | |
| CFB at Final Follow-up (n=58, 63) | -1.03 (\pm 4.95) | 0.66 (\pm 7.17) | | |
| CFB at Extension Follow-up Month 6 (n=7, 18) | 1.45 (\pm 5.16) | 2.61 (\pm 7.46) | | |
| CFB at Extension Follow-up Month 18 (n=1, 1) | -2 (\pm 99999) | 0 (\pm 99999) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: CFB in FACT-Lym-Lymphoma Sub-scale Score

| | |
|-----------------|--|
| End point title | CFB in FACT-Lym-Lymphoma Sub-scale Score |
|-----------------|--|

End point description:

FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0 (Not at all) to 4 (Very much). Total score range: 0-168. Lymphoma sub-scale includes 15 items measured on 0-4 point scale; total score ranges from 0-60. Higher scores indicates better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction); extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up). ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome and "n" signified those participants who were evaluable for a specified time point. The number 99999

signified data not available either because no participant or only one participant was evaluable.

| | |
|--|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline, Day 1 of Cycles 1, 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6 and 18 | |

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|--|--------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 183 | 144 | | |
| Units: units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=183, 144) | 44.88 (± 9.56) | 45.55 (± 9.18) | | |
| CFB at Cycle 1 Day 1 (n=0, 0) | 99999 (± 99999) | 99999 (± 99999) | | |
| CFB at Cycle 3 Day 1 (n=144, 155) | 0.68 (± 6.95) | 1.05 (± 5.58) | | |
| CFB at Cycle 4 Day 1 (n=5, 2) | -2.8 (± 5.76) | 9.5 (± 3.54) | | |
| CFB at Cycle 5 Day 1 (n=130, 143) | 0.88 (± 6.87) | 1.26 (± 6.1) | | |
| CFB at End of Induction Treatment (n=131, 141) | 1.88 (± 7.18) | 0.79 (± 7.99) | | |
| CFB at Follow-up Month 2 (n=90, 121) | 3.63 (± 6.86) | 2.48 (± 6.19) | | |
| CFB at Follow-up Month 4 (n=81, 109) | 2.7 (± 7.08) | 2.55 (± 6.3) | | |
| CFB at Follow-up Month 6 (n=69, 97) | 2.57 (± 6.65) | 3.45 (± 6.36) | | |
| CFB at Follow-up Month 8 (n=61, 88) | 1.63 (± 6.16) | 3.04 (± 6.34) | | |
| CFB at Follow-up Month 10 (n=47, 72) | 1.69 (± 7.1) | 2.61 (± 6.41) | | |
| CFB at Follow-up Month 12 (n=38, 73) | 2.53 (± 7.35) | 3.23 (± 6.5) | | |
| CFB at Follow-up Month 14 (n=32, 65) | 0.37 (± 7.27) | 3.09 (± 6.02) | | |
| CFB at Follow-up Month 16 (n=25, 61) | 0 (± 9.58) | 3.62 (± 6.5) | | |
| CFB at Follow-up Month 18 (n=23, 51) | 1.69 (± 7.33) | 3.07 (± 7.37) | | |
| CFB at Follow-up Month 20 (n=21, 42) | 1.33 (± 8.47) | 3.14 (± 7.4) | | |
| CFB at Follow-up Month 22 (n=16, 38) | 1.19 (± 8.24) | 3.17 (± 6.94) | | |
| CFB at Follow-up Month 24 (n=15, 33) | 0.4 (± 5.91) | 3.25 (± 6.97) | | |
| CFB at Final Follow-up (n=58, 61) | 1.27 (± 7.04) | 1.6 (± 7.73) | | |
| CFB at Extension Follow-up Month 6 (n=7, 17) | 1.29 (± 5.5) | 4.95 (± 8.23) | | |
| CFB at Extension Follow-up Month 18 (n=1, 1) | -4 (± 99999) | 4 (± 99999) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: CFB in Euro Quality of Life 5 Dimension (EuroQoL-5D/EQ-5D) - Health State Profile Utility Score During Induction Phase

| | |
|-----------------|--|
| End point title | CFB in Euro Quality of Life 5 Dimension (EuroQoL-5D/EQ-5D) - Health State Profile Utility Score During Induction Phase |
|-----------------|--|

End point description:

EQ-5D: participant rated questionnaire which assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression; 1 indicates better health state; 3 indicates worst health state. Score is transformed, results in total score range -0.594 to 1.000; higher score indicates better health state. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). For 'Obinutuzumab+Bendamustine' arm, participants who had follow-up Months 2 and 4 visits before start of maintenance treatment were reported in induction phase under "CFB at Follow-up Month 2" and "CFB at Follow-up Month 4" categories. ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome; "n" signified those participants who were evaluable for specified time point. Number 99999 signified data not available as no participant was evaluable.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Day 1 of Cycles 1, 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, and 4

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|--|--------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 180 | 185 | | |
| Units: units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=180, 185) | 0.77 (± 0.23) | 0.79 (± 0.2) | | |
| CFB at Cycle 1 Day 1 (n=0, 0) | 99999 (± 99999) | 99999 (± 99999) | | |
| CFB at Cycle 3 Day 1 (n=147, 156) | 0.03 (± 0.21) | 0 (± 0.2) | | |
| CFB at Cycle 4 Day 1 (n=5, 3) | -0.1 (± 0.23) | -0.07 (± 0.41) | | |
| CFB at Cycle 5 Day 1 (n=130, 146) | 0.01 (± 0.21) | 0.02 (± 0.22) | | |
| CFB at End of Induction Treatment (n=123, 135) | 0.03 (± 0.2) | 0 (± 0.22) | | |
| CFB at Follow-up Month 2 (n=32, 122) | 0.07 (± 0.26) | 0.03 (± 0.15) | | |
| CFB at Follow-up Month 4 (n=0, 2) | 99999 (± 99999) | -0.12 (± 0) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: CFB in EuroQol 5D (EQ-5D) - Health State Profile Utility Score During Maintenance Phase

| | |
|-----------------|--|
| End point title | CFB in EuroQol 5D (EQ-5D) - Health State Profile Utility Score During Maintenance Phase ^[2] |
|-----------------|--|

End point description:

EQ-5D: participant rated questionnaire to assess health-related QoL in terms of single utility score. It assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression; 1 indicates better health state; 3 indicates worst health state. Score is transformed and results in total score range -0.594 to 1.000; higher score indicates better health state. Data for this outcome was planned to be reported only for 'Obinutuzumab + Bendamustine' arm as 'Bendamustine Alone' arm did not have maintenance phase treatment. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). Follow-up months were during maintenance phase. ITT population (Obinutuzumab + Bendamustine arm only). Here, number of participants analyzed signified those participants who were evaluable for this

outcome; "n" signified those participants who were evaluable for a specified time point.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final follow-up (up to 2 years after end of induction) (End of induction = up to Month 6)

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was applicable for only "Obinutuzumab + Bendamustine" arm.

| | | | | |
|--------------------------------------|-----------------------------------|--|--|--|
| End point values | Obinutuzumab + Bendamustine | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 143 | | | |
| Units: units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| CFB at Follow-up Month 2 (n=2) | -0.15 (± 0.22) | | | |
| CFB at Follow-up Month 4 (n=106) | 0.02 (± 0.19) | | | |
| CFB at Follow-up Month 6 (n=93) | 0.02 (± 0.16) | | | |
| CFB at Follow-up Month 8 (n=82) | 0.02 (± 0.17) | | | |
| CFB at Follow-up Month 10 (n=70) | 0.03 (± 0.14) | | | |
| CFB at Follow-up Month 12 (n=66) | 0.05 (± 0.14) | | | |
| CFB at Follow-up Month 14 (n=58) | 0.04 (± 0.13) | | | |
| CFB at Follow-up Month 16 (n=56) | 0.03 (± 0.14) | | | |
| CFB at Follow-up Month 18 (n=47) | 0.03 (± 0.12) | | | |
| CFB at Follow-up Month 20 (n=40) | 0.05 (± 0.13) | | | |
| CFB at Follow-up Month 22 (n=39) | 0.04 (± 0.21) | | | |
| CFB at Follow-up Month 24 (n=33) | 0.02 (± 0.21) | | | |
| CFB at Final Follow-up (n=21) | 0.02 (± 0.13) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: CFB in EQ-5D Visual Analogue Scale (VAS) Score During Induction Phase

| | |
|-----------------|---|
| End point title | CFB in EQ-5D Visual Analogue Scale (VAS) Score During Induction Phase |
|-----------------|---|

End point description:

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate better health state. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). For 'Obinutuzumab + Bendamustine' arm, participants who had their follow-up Month 2 and 4 visits before start of maintenance treatment were reported in induction phase results under "CFB at Follow-up Month 2" and "CFB at Follow-up Month 4" categories. ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome and "n" signified those participants who were evaluable for a specified time point. The number 99999 signified data not available because no participant was evaluable for this time point.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Day 1 of Cycles 1, 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2 and 4

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|--|--------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 178 | 178 | | |
| Units: units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=178, 178) | -69.39 (± 20.61) | 68.03 (± 21.33) | | |
| CFB at Cycle 1 Day 1 (n=0, 0) | 99999 (± 99999) | 99999 (± 99999) | | |
| CFB at Cycle 3 Day 1 (n=143, 146) | 0.5 (± 19.26) | 3.48 (± 16.09) | | |
| CFB at Cycle 4 Day 1 (n=5, 3) | -14 (± 33.29) | -4.33 (± 42.15) | | |
| CFB at Cycle 5 Day 1 (n=125, 133) | -0.29 (± 20.89) | 5.26 (± 17.66) | | |
| CFB at End of Induction Treatment (n=119, 129) | 6.75 (± 64.84) | 6.09 (± 22.48) | | |
| CFB at Follow-up Month 2 (n=30, 114) | 5.2 (± 20.48) | 7.43 (± 18.97) | | |
| CFB at Follow-up Month 4 (n=0, 2) | 99999 (± 99999) | 0 (± 14.14) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: CFB in EQ-5D VAS Score During Maintenance Phase

| | |
|-----------------|--|
| End point title | CFB in EQ-5D VAS Score During Maintenance Phase ^[3] |
|-----------------|--|

End point description:

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Data for this outcome was planned to be reported only for 'Obinutuzumab + Bendamustine' arm. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). Follow-up months were during maintenance phase. ITT population (Obinutuzumab + Bendamustine arm only). Here, number of participants analyzed signified those participants who were evaluable for this outcome and "n" signified those participants who were evaluable for a specified time point. The number 99999 signified data not available as only one participant was evaluable for this time point.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction) (end of induction = up to Month 6)

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was applicable for only "Obinutuzumab + Bendamustine" arm.

| | | | | |
|--------------------------------------|-----------------------------------|--|--|--|
| End point values | Obinutuzumab + Bendamustine | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 143 | | | |
| Units: units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| CFB at Follow-up Month 2 (n=1) | -40 (± 99999) | | | |
| CFB at Follow-up Month 4 (n=98) | 5.96 (± 19.8) | | | |
| CFB at Follow-up Month 6 (n=87) | 7.21 (± 18.91) | | | |
| CFB at Follow-up Month 8 (n=76) | 5.62 (± 16.78) | | | |
| CFB at Follow-up Month 10 (n=65) | 6.08 (± 15.26) | | | |
| CFB at Follow-up Month 12 (n=62) | 5.82 (± 16.57) | | | |
| CFB at Follow-up Month 14 (n=54) | 6.76 (± 16.59) | | | |
| CFB at Follow-up Month 16 (n=53) | 6.91 (± 18.37) | | | |
| CFB at Follow-up Month 18 (n=44) | 4.5 (± 20.6) | | | |
| CFB at Follow-up Month 20 (n=38) | 5.76 (± 16.48) | | | |
| CFB at Follow-up Month 22 (n=35) | 6.14 (± 17.3) | | | |
| CFB at Follow-up Month 24 (n=30) | 5.67 (± 18.71) | | | |
| CFB at Final Follow-up (n=20) | 1.05 (± 9.48) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: CFB in Functional Assessment of Cancer Therapy - Generic (FACT-G) Score

| | |
|-----------------|---|
| End point title | CFB in Functional Assessment of Cancer Therapy - Generic (FACT-G) Score |
|-----------------|---|

End point description:

The FACT-G is the sum of 4 sub-scales (physical, social, emotional and functional well-being) of FACT-Lym which includes total 27 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-108. Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up). ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome and "n" signified those participants who were evaluable for a specified time point. The Number 99999 signified data not available either because no participant or only one participant was evaluable.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Day 1 of Cycles 1, 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6 and 18

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|--|--------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 179 | 177 | | |
| Units: units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=179, 177) | 80.07 (± 15.87) | 80.61 (± 16.19) | | |
| CFB at Cycle 1 Day 1 (n=0, 0) | 99999 (± 99999) | 99999 (± 99999) | | |
| CFB at Cycle 3 Day 1 (n=144, 147) | -2.43 (± 12.28) | -0.02 (± 10.49) | | |
| CFB at Cycle 4 Day 1 (n=5, 2) | -9.37 (± 9.89) | 0.52 (± 4.98) | | |
| CFB at Cycle 5 Day 1 (n=128, 137) | -3.28 (± 11.72) | -0.04 (± 11.37) | | |
| CFB at End of Induction Treatment (n=129, 133) | -2.23 (± 13.8) | -1.08 (± 11.87) | | |
| CFB at Follow-up Month 2 (n=90, 119) | 0.96 (± 13.78) | 1.15 (± 12) | | |
| CFB at Follow-up Month 4 (n=80, 107) | 2.34 (± 11.13) | 2.84 (± 12.92) | | |
| CFB at Follow-up Month 6 (n=65, 93) | 2.28 (± 10.1) | 3.33 (± 11.52) | | |
| CFB at Follow-up Month 8 (n=61, 86) | -0.54 (± 10.15) | 2.14 (± 11.73) | | |
| CFB at Follow-up Month 10 (n=46, 68) | 1.17 (± 11.14) | 3.44 (± 12.4) | | |
| CFB at Follow-up Month 12 (n=38, 70) | 1.63 (± 11.44) | 2.98 (± 15.28) | | |
| CFB at Follow-up Month 14 (n=32, 61) | 2.77 (± 9.85) | 2.44 (± 12.25) | | |
| CFB at Follow-up Month 16 (n=26, 59) | 0.8 (± 8.22) | 4.37 (± 13.4) | | |
| CFB at Follow-up Month 18 (n=22, 50) | 0.65 (± 12.12) | 3.99 (± 15.03) | | |
| CFB at Follow-up Month 20 (n=22, 41) | -2.2 (± 12.18) | 2.98 (± 16.64) | | |
| CFB at Follow-up Month 22 (n=16, 38) | -3.97 (± 12.71) | 0.86 (± 13.96) | | |
| CFB at Follow-up Month 24 (n=15, 33) | -4.43 (± 8.13) | 2.57 (± 15.49) | | |
| CFB at Final Follow-up (n=58, 58) | -1.47 (± 11.29) | 0.72 (± 17.13) | | |
| CFB at Extension Follow Up Month 6 (n=7, 18) | 0.52 (± 11.58) | 5.46 (± 15.99) | | |
| CFB at Extension Follow Up Month 18 (n=1, 1) | -1 (± 99999) | 25 (± 99999) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: CFB in FACT-Lym Trial Outcome Index (TOI)

| | |
|-----------------|---|
| End point title | CFB in FACT-Lym Trial Outcome Index (TOI) |
|-----------------|---|

End point description:

TOI is the sum of 3 sub-scales (physical well-being, functional well-being, and Lymphoma sub-scale) of FACT-Lym which includes total 29 items; responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0–116. Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up). ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome and "n" signified those participants who were evaluable for a specified time point. The Number 99999 signified data not available either because no participant or only one participant was evaluable.

| | |
|--|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline, Day 1 of Cycles 1, 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6 and 18 | |

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|--|--------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 184 | 186 | | |
| Units: units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=184, 186) | 84.79 (± 19.01) | 84.53 (± 19.03) | | |
| CFB at Cycle 1 Day 1 (n=0, 0) | 99999 (± 99999) | 99999 (± 99999) | | |
| CFB at Cycle 3 Day 1 (n=149, 158) | -2.61 (± 18.09) | 1.6 (± 14.03) | | |
| CFB at Cycle 4 Day 1 (n=5, 3) | -10.4 (± 10.38) | 26.44 (± 19.51) | | |
| CFB at Cycle 5 Day 1 (n=132, 146) | -1.55 (± 15.6) | 2.23 (± 14.34) | | |
| CFB at End of Induction Treatment (n=134, 142) | -0.4 (± 17.9) | 0.44 (± 16.73) | | |
| CFB at Follow-up Month 2 (n=91, 125) | 3.63 (± 15.93) | 4.81 (± 14.98) | | |
| CFB at Follow-up Month 4 (n=81, 113) | 3.75 (± 13.67) | 5.16 (± 17.03) | | |
| CFB at Follow-up Month 6 (n=69, 97) | 3.34 (± 12.36) | 6.56 (± 13.08) | | |
| CFB at Follow-up Month 8 (n=62, 89) | 0.68 (± 12.96) | 6.25 (± 14.09) | | |
| CFB at Follow-up Month 10 (n=47, 74) | 2.42 (± 13.99) | 5.3 (± 16.66) | | |
| CFB at Follow-up Month 12 (n=38, 73) | 4.14 (± 14.46) | 6.92 (± 16.37) | | |
| CFB at Follow-up Month 14 (n=32, 65) | 1.98 (± 12.49) | 5.82 (± 14.5) | | |
| CFB at Follow-up Month 16 (n=26, 62) | -1.46 (± 15.97) | 6.93 (± 16.65) | | |
| CFB at Follow-up Month 18 (n=23, 52) | 0.69 (± 12.84) | 7.57 (± 16.55) | | |
| CFB at Follow-up Month 20 (n=22, 44) | -2.03 (± 16.54) | 7.01 (± 18.23) | | |
| CFB at Follow-up Month 22 (n=16, 41) | -1.28 (± 11.66) | 3.29 (± 23.02) | | |
| CFB at Follow-up Month 24 (n=15, 35) | -2.69 (± 10.7) | 6.75 (± 21.25) | | |
| CFB at Final Follow-up (n=59, 63) | -0.9 (± 15.31) | 4.8 (± 18.47) | | |
| CFB at Extension Follow Up Month 6 (n=7, 18) | 3.05 (± 11.34) | 5.6 (± 20.67) | | |
| CFB at Extension Follow Up Month 18 (n=1, 1) | -5 (± 99999) | 11 (± 99999) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: CFB in FACT-Lym Total Score

| | |
|-----------------|-----------------------------|
| End point title | CFB in FACT-Lym Total Score |
|-----------------|-----------------------------|

End point description:

FACT-Lym total score: sum of physical well-being score (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and Lymphoma sub-scale (15 items); responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0–168. Higher scores indicate better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up). ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome and "n" signified those participants who were evaluable for a specified time point. Number 99999 signified data not available either because no participant or only one participant was evaluable.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Day 1 of Cycles 1, 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6 and 18

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|--|--------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 180 | 177 | | |
| Units: units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=180, 177) | 124.86 (± 23.63) | 126 (± 23.96) | | |
| CFB at Cycle 1 Day 1 (n=0, 0) | 99999 (± 99999) | 99999 (± 99999) | | |
| CFB at Cycle 3 Day 1 (n=143, 147) | -1.61 (± 17.85) | 1 (± 13.96) | | |
| CFB at Cycle 4 Day 1 (n=5, 2) | -12.16 (± 14.8) | 22.53 (± 16.23) | | |
| CFB at Cycle 5 Day 1 (n=128, 136) | -2.37 (± 16.63) | 1.47 (± 15.44) | | |
| CFB at End of Induction Treatment (n=130, 133) | -0.11 (± 18.91) | 0.25 (± 18.5) | | |
| CFB at Follow-up Month 2 (89, 117) | 4.74 (± 18.22) | 3.48 (± 15.18) | | |
| CFB at Follow-up Month 4 (n=80, 105) | 5.14 (± 16.39) | 5.57 (± 17.28) | | |
| CFB at Follow-up Month 6 (n=66, 95) | 5.08 (± 14.88) | 6.85 (± 15.59) | | |
| CFB at Follow-up Month 8 (n=61, 86) | 1.23 (± 14.48) | 5.46 (± 15.84) | | |
| CFB at Follow-up Month 10 (n=47, 70) | 3.2 (± 16.87) | 5.74 (± 17.58) | | |
| CFB at Follow-up Month 12 (n= 38, 71) | 4.19 (± 17.76) | 6.41 (± 20.02) | | |
| CFB at Follow-up Month 14 (n= 32, 62) | 3.13 (± 14.51) | 5.97 (± 17.35) | | |
| CFB at Follow-up Month 16 (n=25, 59) | 1.18 (± 14.22) | 8.49 (± 17.45) | | |
| CFB at Follow-up Month 18 (n=22, 49) | 2.11 (± 16.99) | 7.33 (± 20.14) | | |
| CFB at Follow-up Month 20 (n=21, 40) | -0.92 (± 16.7) | 6.16 (± 21.85) | | |
| CFB at Follow-up Month 22 (n=16, 37) | -2.66 (± 14.13) | 4.74 (± 20.21) | | |
| CFB at Follow-up Month 24 (n=15, 32) | -3.98 (± 11.86) | 6.11 (± 21.48) | | |
| CFB at Final follow-up (n=58, 56) | -0.18 (± 16.66) | 2.86 (± 22.89) | | |
| CFB at Extension Follow Up Month 6 (n=7, 17) | 1.8 (± 16.55) | 10.93 (± 22.57) | | |
| CFB at Extension Follow Up Month 18 (n=1, 1) | -5 (± 99999) | 29 (± 99999) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Deterioration of FACT-Lym TOI

| | |
|-----------------|---------------------------------------|
| End point title | Time to Deterioration of FACT-Lym TOI |
|-----------------|---------------------------------------|

End point description:

The median time, in month, from date of randomization until a clinically meaningful decline from baseline in TOI or death, whichever occurred first. TOI: sum of physical well-being score, functional well-being score, and Lymphoma sub-scale of FACT-Lym; total 29 items, responses to each item range from 0, "Not at all" to 4, "Very much". Total score ranges from 0-116. Higher scores indicate a better PRO/QoL. A clinically meaningful decline in TOI score was defined as at least a 6 point decline from baseline. Time to deterioration was estimated using Kaplan-Meier method and 95% CI for median was computed using the method of Brookmeyer and Crowley. In timeframe, follow-up months represents months after end of induction (EOI) (e.g. Follow-up Month 2 is 2 months after EOI) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up). ITT population.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to approximately 4 years (Baseline, Day 1 of Cycles 1, 3, 4, 5, EOI treatment [up to Month 6]; Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up [up to 2 years after EOI]; Extension follow-up Months 6 and 18)

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|----------------------------------|--------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 202 | 194 | | |
| Units: months | | | | |
| median (confidence interval 95%) | 4.6 (3.8 to 6.4) | 8 (5.8 to 15.1) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Definitive Improvement (DI) From Baseline in FACT-Lym Instrument Scores

| | |
|-----------------|---|
| End point title | Percentage of Participants With Definitive Improvement (DI) From Baseline in FACT-Lym Instrument Scores |
|-----------------|---|

End point description:

FACT-Lym: 42-items in 5 subscales. Responses to each item range from 0 (Not at all) to 4 (Very much). FACT-Lym Lymphoma subscale includes 15 items (total score range = 0-60). FACT-Lym TOI is sum of 3 subscales (physical well-being, functional well-being, lymphoma subscale) and includes 29 items (total score range = 0-116). FACT-Lym total score is sum of 42 items (total score ranges from 0-168). For all above, higher scores indicate a better PRO/QoL. DI from baseline: at least 3 point increase from

baseline in FACT-Lym Lymphoma subscale; at least 6 point increase from baseline in FACT Lym TOI; at least 7 point increase from baseline in FACT Lym total scores. In timeframe, follow-up months represents months after EOI (e.g. Follow-up Month 2 is 2 months after EOI; EOI = up to Month 6). ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome and "n" signified those participants who were evaluable for a specified category.

| | |
|--|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline, Cycle 5 Day 1 (C5D1) (Cycle length = 28 days), Follow-up Months 6 (FUM6), and 12 (FUM12) | |

| End point values | Bendamustine Alone | Obinutuzumab + Bendamustine | | |
|---|--------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 184 | 186 | | |
| Units: percentage of participants | | | | |
| number (not applicable) | | | | |
| DI in Lymphoma sub-scale: C5D1 (n=142, 148) | 31 | 41.2 | | |
| DI in Lymphoma sub-scale: FUM6 (n=76, 99) | 38.2 | 48.5 | | |
| DI in Lymphoma sub-scale: FUM12 (n=44, 77) | 38.6 | 48.1 | | |
| DI in FACT Lym TOI: C5D1 (n=143, 149) | 22.4 | 34.9 | | |
| DI in FACT Lym TOI: FUM6 (n=77, 99) | 28.6 | 43.4 | | |
| DI in FACT Lym TOI: FUM12 (n=44, 77) | 27.3 | 48.1 | | |
| DI in FACT Total: C5D1 (n=143, 149) | 23.1 | 27.5 | | |
| DI in FACT Total: FUM6 (n=77, 99) | 33.8 | 42.4 | | |
| DI in FACT Total: FUM12 (n=44, 77) | 29.5 | 45.5 | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to 4.5 years

Adverse event reporting additional description:

Safety population included all participants who received any amount of obinutuzumab or bendamustine therapy.

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 17.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|-----------------------------|
| Reporting group title | Obinutuzumab + Bendamustine |
|-----------------------|-----------------------------|

Reporting group description:

Induction phase: Participants received Bendamustine 90 mg/m² IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6.

Maintenance phase: Participants received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).

| | |
|-----------------------|--------------------|
| Reporting group title | Bendamustine Alone |
|-----------------------|--------------------|

Reporting group description:

Participants received Bendamustine 120 mg/m² IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.

| Serious adverse events | Obinutuzumab + Bendamustine | Bendamustine Alone | |
|---|-----------------------------|--------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 74 / 194 (38.14%) | 65 / 198 (32.83%) | |
| number of deaths (all causes) | 42 | 56 | |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Acute myeloid leukaemia | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 1 / 1 | 1 / 1 | |
| Adenocarcinoma | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Bladder cancer | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholangiocarcinoma | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colorectal cancer | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Leiomyosarcoma | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Leukaemia | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 2 / 198 (1.01%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | |
| Malignant melanoma | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myelodysplastic syndrome | | | |
| subjects affected / exposed | 2 / 194 (1.03%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 2 / 2 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paraneoplastic pemphigus | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Polycythaemia vera | | | |

| | | | |
|--|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal cancer | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Squamous cell carcinoma | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| T-cell lymphoma | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Thyroid neoplasm | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypotension | | | |
| subjects affected / exposed | 2 / 194 (1.03%) | 2 / 198 (1.01%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Chest pain | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 2 / 198 (1.01%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|-----------------|-----------------|--|
| General physical health deterioration | | | |
| subjects affected / exposed | 2 / 194 (1.03%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperthermia | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malaise | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyrexia | | | |
| subjects affected / exposed | 5 / 194 (2.58%) | 3 / 198 (1.52%) | |
| occurrences causally related to treatment / all | 2 / 5 | 1 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Immune system disorders | | | |
| Graft versus host disease | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Social circumstances | | | |
| Social problem | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Social stay hospitalisation | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|-----------------|-----------------|--|
| Reproductive system and breast disorders | | | |
| Benign prostatic hyperplasia | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Bronchospasm | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chylothorax | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Emphysema | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoxia | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumothorax | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary embolism | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 3 / 198 (1.52%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mania | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Investigations | | | |
| Blood creatinine increased | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Femur fracture | | | |
| subjects affected / exposed | 2 / 194 (1.03%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Head injury | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hip fracture | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|-----------------|-----------------|--|
| Infusion related reaction | | | |
| subjects affected / exposed | 6 / 194 (3.09%) | 3 / 198 (1.52%) | |
| occurrences causally related to treatment / all | 6 / 6 | 3 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Jaw fracture | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post procedural bile leak | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Seroma | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Stab wound | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular pseudoaneurysm | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | |
| Wrist fracture | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 2 / 194 (1.03%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 2 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial flutter | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac failure | | | |
| subjects affected / exposed | 2 / 194 (1.03%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery disease | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocardial infarction | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paroxysmal arrhythmia | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Central nervous system lesion | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Headache | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ischaemic stroke | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Presyncope | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subarachnoid haemorrhage | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Syncope | | | |
| subjects affected / exposed | 2 / 194 (1.03%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| Agranulocytosis | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Anaemia | | | |
| subjects affected / exposed | 3 / 194 (1.55%) | 3 / 198 (1.52%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Febrile neutropenia | | | |
| subjects affected / exposed | 8 / 194 (4.12%) | 6 / 198 (3.03%) | |
| occurrences causally related to treatment / all | 12 / 13 | 6 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neutropenia | | | |
| subjects affected / exposed | 6 / 194 (3.09%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 5 / 6 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombocytopenia | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 4 / 194 (2.06%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 4 / 4 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Eye disorders | | | |
| Necrotising retinitis | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anal fissure | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colitis | | | |
| subjects affected / exposed | 2 / 194 (1.03%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 4 / 198 (2.02%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematochezia | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal perforation | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Large intestinal obstruction | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Melaena | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nausea | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatitis | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 2 / 194 (1.03%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vomiting | | | |
| subjects affected / exposed | 2 / 194 (1.03%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Cholecystitis | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Dysuria | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematuria | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pollakiuria | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal failure chronic | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Ureteric obstruction | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary incontinence | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Muscle haemorrhage | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|-----------------|-----------------|--|
| Osteoarthritis | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Atypical pneumonia | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 2 / 198 (1.01%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchopneumonia | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Device related infection | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endocarditis | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Escherichia sepsis | | | |
| subjects affected / exposed | 2 / 194 (1.03%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Fungal sepsis | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Gastroenteritis | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Gastroenteritis norovirus | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatitis B | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Herpes zoster | | | |
| subjects affected / exposed | 2 / 194 (1.03%) | 3 / 198 (1.52%) | |
| occurrences causally related to treatment / all | 2 / 2 | 3 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infection | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 2 / 198 (1.01%) | |
| occurrences causally related to treatment / all | 0 / 0 | 2 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 3 / 194 (1.55%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 1 / 3 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung infection | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neutropenic sepsis | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Pneumocystis jirovecii pneumonia | | | |

| | | | |
|---|-----------------|------------------|--|
| subjects affected / exposed | 1 / 194 (0.52%) | 2 / 198 (1.01%) | |
| occurrences causally related to treatment / all | 0 / 1 | 2 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 2 / 2 | |
| Pneumonia | | | |
| subjects affected / exposed | 5 / 194 (2.58%) | 10 / 198 (5.05%) | |
| occurrences causally related to treatment / all | 2 / 5 | 6 / 10 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Pneumonia cytomegaloviral | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pseudomonal sepsis | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | |
| Sepsis | | | |
| subjects affected / exposed | 6 / 194 (3.09%) | 7 / 198 (3.54%) | |
| occurrences causally related to treatment / all | 3 / 6 | 4 / 7 | |
| deaths causally related to treatment / all | 0 / 1 | 1 / 3 | |
| Sinusitis | | | |
| subjects affected / exposed | 2 / 194 (1.03%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Staphylococcal sepsis | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tooth infection | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper respiratory tract infection | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 2 / 194 (1.03%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 3 / 194 (1.55%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urosepsis | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 2 / 198 (1.01%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 1 / 194 (0.52%) | 0 / 198 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 1 / 198 (0.51%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tumour lysis syndrome | | | |
| subjects affected / exposed | 0 / 194 (0.00%) | 2 / 198 (1.01%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Obinutuzumab + Bendamustine | Bendamustine Alone | |
|---|------------------------------------|---------------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 187 / 194 (96.39%) | 187 / 198 (94.44%) | |
| Vascular disorders | | | |
| Hypotension | | | |
| subjects affected / exposed | 22 / 194 (11.34%) | 1 / 198 (0.51%) | |
| occurrences (all) | 25 | 2 | |
| Phlebitis | | | |
| subjects affected / exposed | 11 / 194 (5.67%) | 13 / 198 (6.57%) | |
| occurrences (all) | 11 | 14 | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 29 / 194 (14.95%) | 23 / 198 (11.62%) | |
| occurrences (all) | 40 | 32 | |
| Chest pain | | | |
| subjects affected / exposed | 10 / 194 (5.15%) | 3 / 198 (1.52%) | |
| occurrences (all) | 10 | 3 | |
| Chills | | | |
| subjects affected / exposed | 24 / 194 (12.37%) | 20 / 198 (10.10%) | |
| occurrences (all) | 26 | 23 | |
| Fatigue | | | |
| subjects affected / exposed | 76 / 194 (39.18%) | 66 / 198 (33.33%) | |
| occurrences (all) | 144 | 113 | |
| Oedema peripheral | | | |
| subjects affected / exposed | 12 / 194 (6.19%) | 14 / 198 (7.07%) | |
| occurrences (all) | 13 | 17 | |
| Pain | | | |
| subjects affected / exposed | 5 / 194 (2.58%) | 10 / 198 (5.05%) | |
| occurrences (all) | 6 | 10 | |
| Pyrexia | | | |
| subjects affected / exposed | 50 / 194 (25.77%) | 33 / 198 (16.67%) | |
| occurrences (all) | 74 | 40 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 54 / 194 (27.84%) | 34 / 198 (17.17%) | |
| occurrences (all) | 72 | 39 | |

| | | | |
|--|--------------------|--------------------|--|
| Dyspnoea | | | |
| subjects affected / exposed | 22 / 194 (11.34%) | 21 / 198 (10.61%) | |
| occurrences (all) | 23 | 26 | |
| Nasal congestion | | | |
| subjects affected / exposed | 16 / 194 (8.25%) | 5 / 198 (2.53%) | |
| occurrences (all) | 17 | 6 | |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 11 / 194 (5.67%) | 7 / 198 (3.54%) | |
| occurrences (all) | 14 | 7 | |
| Rhinorrhoea | | | |
| subjects affected / exposed | 11 / 194 (5.67%) | 3 / 198 (1.52%) | |
| occurrences (all) | 11 | 3 | |
| Psychiatric disorders | | | |
| Insomnia | | | |
| subjects affected / exposed | 21 / 194 (10.82%) | 21 / 198 (10.61%) | |
| occurrences (all) | 24 | 26 | |
| Investigations | | | |
| Weight decreased | | | |
| subjects affected / exposed | 9 / 194 (4.64%) | 17 / 198 (8.59%) | |
| occurrences (all) | 9 | 17 | |
| Injury, poisoning and procedural complications | | | |
| Infusion related reaction | | | |
| subjects affected / exposed | 123 / 194 (63.40%) | 113 / 198 (57.07%) | |
| occurrences (all) | 281 | 238 | |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 13 / 194 (6.70%) | 17 / 198 (8.59%) | |
| occurrences (all) | 20 | 23 | |
| Dysgeusia | | | |
| subjects affected / exposed | 15 / 194 (7.73%) | 16 / 198 (8.08%) | |
| occurrences (all) | 20 | 20 | |
| Headache | | | |
| subjects affected / exposed | 26 / 194 (13.40%) | 32 / 198 (16.16%) | |
| occurrences (all) | 35 | 37 | |
| Blood and lymphatic system disorders | | | |

| | | | |
|-----------------------------|--------------------|--------------------|--|
| Anaemia | | | |
| subjects affected / exposed | 23 / 194 (11.86%) | 28 / 198 (14.14%) | |
| occurrences (all) | 36 | 34 | |
| Neutropenia | | | |
| subjects affected / exposed | 66 / 194 (34.02%) | 56 / 198 (28.28%) | |
| occurrences (all) | 126 | 92 | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 26 / 194 (13.40%) | 47 / 198 (23.74%) | |
| occurrences (all) | 54 | 87 | |
| Gastrointestinal disorders | | | |
| Abdominal distension | | | |
| subjects affected / exposed | 7 / 194 (3.61%) | 11 / 198 (5.56%) | |
| occurrences (all) | 7 | 12 | |
| Abdominal pain | | | |
| subjects affected / exposed | 12 / 194 (6.19%) | 18 / 198 (9.09%) | |
| occurrences (all) | 13 | 21 | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 10 / 194 (5.15%) | 15 / 198 (7.58%) | |
| occurrences (all) | 11 | 19 | |
| Constipation | | | |
| subjects affected / exposed | 41 / 194 (21.13%) | 38 / 198 (19.19%) | |
| occurrences (all) | 54 | 53 | |
| Diarrhoea | | | |
| subjects affected / exposed | 53 / 194 (27.32%) | 59 / 198 (29.80%) | |
| occurrences (all) | 71 | 78 | |
| Dry mouth | | | |
| subjects affected / exposed | 8 / 194 (4.12%) | 11 / 198 (5.56%) | |
| occurrences (all) | 8 | 14 | |
| Dyspepsia | | | |
| subjects affected / exposed | 12 / 194 (6.19%) | 8 / 198 (4.04%) | |
| occurrences (all) | 15 | 10 | |
| Nausea | | | |
| subjects affected / exposed | 104 / 194 (53.61%) | 121 / 198 (61.11%) | |
| occurrences (all) | 204 | 220 | |
| Vomiting | | | |

| | | | |
|--|-------------------------|-------------------------|--|
| subjects affected / exposed occurrences (all) | 42 / 194 (21.65%) 63 | 54 / 198 (27.27%) 87 | |
| Skin and subcutaneous tissue disorders | | | |
| Erythema | | | |
| subjects affected / exposed | 10 / 194 (5.15%) | 4 / 198 (2.02%) | |
| occurrences (all) | 11 | 4 | |
| Pruritus | | | |
| subjects affected / exposed | 25 / 194 (12.89%) | 12 / 198 (6.06%) | |
| occurrences (all) | 33 | 13 | |
| Rash | | | |
| subjects affected / exposed | 24 / 194 (12.37%) | 23 / 198 (11.62%) | |
| occurrences (all) | 30 | 26 | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 23 / 194 (11.86%) | 9 / 198 (4.55%) | |
| occurrences (all) | 28 | 10 | |
| Back pain | | | |
| subjects affected / exposed | 13 / 194 (6.70%) | 18 / 198 (9.09%) | |
| occurrences (all) | 14 | 22 | |
| Myalgia | | | |
| subjects affected / exposed | 12 / 194 (6.19%) | 15 / 198 (7.58%) | |
| occurrences (all) | 13 | 17 | |
| Pain in extremity | | | |
| subjects affected / exposed | 18 / 194 (9.28%) | 10 / 198 (5.05%) | |
| occurrences (all) | 22 | 13 | |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 18 / 194 (9.28%) | 17 / 198 (8.59%) | |
| occurrences (all) | 29 | 21 | |
| Herpes zoster | | | |
| subjects affected / exposed | 6 / 194 (3.09%) | 13 / 198 (6.57%) | |
| occurrences (all) | 6 | 15 | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 17 / 194 (8.76%) | 8 / 198 (4.04%) | |
| occurrences (all) | 22 | 10 | |
| Sinusitis | | | |

| | | | |
|------------------------------------|-------------------|-------------------|--|
| subjects affected / exposed | 22 / 194 (11.34%) | 10 / 198 (5.05%) | |
| occurrences (all) | 32 | 12 | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 23 / 194 (11.86%) | 15 / 198 (7.58%) | |
| occurrences (all) | 28 | 18 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 18 / 194 (9.28%) | 11 / 198 (5.56%) | |
| occurrences (all) | 29 | 13 | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 34 / 194 (17.53%) | 35 / 198 (17.68%) | |
| occurrences (all) | 36 | 47 | |
| Hypokalaemia | | | |
| subjects affected / exposed | 14 / 194 (7.22%) | 12 / 198 (6.06%) | |
| occurrences (all) | 20 | 15 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|--|
| 11 December 2009 | The protocol was amended to address feedback from the FDA during the Type B (pre Phase III) meeting held on 03 November 2009. The protocol was amended to modify bendamustine control arm dosing regimen from 90 mg/m ² to 120 mg/m ² which was given on Days 1 and 2 of a 28-day cycle, definition of rituximab-refractoriness was more clearly defined in the inclusion criteria. Eligibility criteria was also modified in order to allow more sites and countries to participate in the study. |
| 28 July 2010 | The protocol was amended to address feedback from the investigators and others since the first version of the protocol was issued. The exclusion criteria was modified to exclude participants who had received bendamustine; definition of rituximab-refractory iNHL was clarified; exclusion criterion regarding contraception was expanded to include participants who received only bendamustine; an early interim analysis for futility was added to the protocol in response to a recommendation by the independent data monitoring committee (IDMC); analysis of the FACT-Lym questionnaire was modified to capture changes in the participant's health-related QoL based on minimally important differences. |
| 07 December 2011 | The protocol was amended to address general issues related to the conduct of the trial, as well as comments from the IDMC, Investigators and study management team. A number of changes were made to eligibility criteria and some parameters were clarified. |
| 01 May 2012 | The protocol was amended to address general issues related to the conduct of the trial. The eligibility criteria was modified to allow for the enrollment of participant's previously treated with a bendamustine-containing regimen to reflect clinical practice so that participant's who were previously bendamustine responders and failed a subsequent regimen containing either an alkylating agent or anthracycline were allowed to participate in the study. |
| 27 November 2012 | This was a country-specific amendment for France to exclude participant's with a history of progressive multifocal encephalopathy (PML). The section on risks associated with obinutuzumab therapy was also updated with information on PML diagnosis, evaluation and guidance on how to manage a potential PML case. |
| 06 March 2013 | The protocol was amended to include revised information about PML; changes were made to some of the efficacy text (PFS assessment, secondary outcome measures and pharmacodynamic assessment) to align the protocol efficacy sections with the statistical analysis plan; requirement of administration of obinutuzumab after bendamustine on days when both drugs are given was deleted, so that the order in which the drugs are given is left to the discretion of the sites. |
| 24 October 2013 | The protocol was amended to allow for an increase in the number of participants enrolled from 360 to 410 and to extend the period of AE reporting in the comparator arm; collection of safety data was made consistent over the same timeframe for both treatment arms to more accurately assess the overall benefit/risk profile of adding obinutuzumab to bendamustine; period of AEs reporting in the comparator arm was extended in response to a recommendation by the IDMC; appendix E was also modified to match the original wording of the revised response criteria for malignant lymphoma and current clinical practice. |
| 10 March 2014 | The protocol was amended following the identification of a higher incidence of thrombocytopenia and hemorrhagic events in participants with chronic lymphocytic leukemia receiving obinutuzumab; guidelines on the management of participant's with thrombocytopenia (especially during the first cycle), and participants receiving anticoagulants or platelet inhibitors were also added. |

| | |
|-------------|--|
| 07 May 2015 | This protocol version is a country-specific amendment implemented in Canada and the Czech Republic. The protocol was amended to offer the choice to participant's in the control arm receiving bendamustine to cross-over to the combination treatment arm (obinutuzumab plus bendamustine). |
|-------------|--|

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported